72 related articles for article (PubMed ID: 28249257)
1. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
Steinacher D; Claudel T; Trauner M
Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
[TBL] [Abstract][Full Text] [Related]
2. A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway.
Islam D; Israr I; Taleb MAB; Rao A; Yosief R; Sultana R; Sampaziotis F; Tysoe OC; Trauner M; Karpen SJ; Ghanekar A; Kamath BM
Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38407207
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid for coronavirus disease 2019 prevention.
Okushin K; Kurano M; ; Yatomi Y; Moriya K; Fujishiro M; Tsutsumi T
J Intern Med; 2024 Jan; 295(1):106-109. PubMed ID: 37470083
[No Abstract] [Full Text] [Related]
4. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
Fujita K; Iguchi Y; Une M; Watanabe S
Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
[TBL] [Abstract][Full Text] [Related]
6. Targeting hepatic macrophages to treat liver diseases.
Tacke F
J Hepatol; 2017 Jun; 66(6):1300-1312. PubMed ID: 28267621
[TBL] [Abstract][Full Text] [Related]
7. Key role of liver sinusoidal endothelial cells in liver fibrosis.
Xu M; Wang X; Zou Y; Zhong Y
Biosci Trends; 2017 May; 11(2):163-168. PubMed ID: 28250338
[TBL] [Abstract][Full Text] [Related]
8. Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review.
Tovo CV; Fernandes SA; Buss C; de Mattos AA
World J Hepatol; 2017 Feb; 9(6):326-332. PubMed ID: 28293382
[TBL] [Abstract][Full Text] [Related]
9. Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function.
Binks AP; Beyer M; Miller R; LeClair RJ
Physiol Rep; 2017 Mar; 5(5):. PubMed ID: 28292882
[TBL] [Abstract][Full Text] [Related]
10. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Cabrera D; Arab JP; Arrese M
Handb Exp Pharmacol; 2019; 256():237-264. PubMed ID: 31236688
[TBL] [Abstract][Full Text] [Related]
11. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S; Schattenberg JM; Demir M; Wiegand J; Geier A; Teuber G; Hofmann WP; Kremer AE; Spreda F; Kluwe J; Petersen J; Boettler T; Rainer F; Halilbasic E; Greinwald R; Pröls M; Manns MP; Fickert P; Trauner M;
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):781-793. PubMed ID: 31345778
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review.
Stan SI; Biciuşcă V; Clenciu D; Mitrea A; Boldeanu MV; Durand P; Dănoiu S
Med Pharm Rep; 2024 Jan; 97(1):12-25. PubMed ID: 38344336
[TBL] [Abstract][Full Text] [Related]
13. Bile salt signaling and bile salt-based therapies in cardiometabolic disease.
Groenen CCJ; Nguyen TA; Paulusma CC; van de Graaf SFJ
Clin Sci (Lond); 2024 Jan; 138(1):1-21. PubMed ID: 38180064
[TBL] [Abstract][Full Text] [Related]
14. Effects of Dietary Bile Acids on Growth Performance, Lipid Deposition, and Intestinal Health of Rice Field Eel (
Lei W; Li J; Fang P; Wu S; Deng Y; Luo A; He Z; Peng M
Aquac Nutr; 2023; 2023():3321734. PubMed ID: 38174087
[TBL] [Abstract][Full Text] [Related]
15. Bile Acids-A Peek Into Their History and Signaling.
Nguyen JT; Shaw RPH; Anakk S
Endocrinology; 2022 Oct; 163(11):. PubMed ID: 36130324
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.
Lee HA; Chang Y; Sung PS; Yoon EL; Lee HW; Yoo JJ; Lee YS; An J; Song DS; Cho YY; Kim SU; Kim YJ
Clin Mol Hepatol; 2022 Jul; 28(3):425-472. PubMed ID: 35850495
[TBL] [Abstract][Full Text] [Related]
17. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.
Satiya J; Snyder HS; Singh SP; Satapathy SK
Transl Gastroenterol Hepatol; 2021; 6():60. PubMed ID: 34805582
[TBL] [Abstract][Full Text] [Related]
18. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
[TBL] [Abstract][Full Text] [Related]
19. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis.
Ganguli S; DeLeeuw P; Satapathy SK
Hepat Med; 2019; 11():159-178. PubMed ID: 31814783
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression.
Segovia-Miranda F; Morales-Navarrete H; Kücken M; Moser V; Seifert S; Repnik U; Rost F; Brosch M; Hendricks A; Hinz S; Röcken C; Lütjohann D; Kalaidzidis Y; Schafmayer C; Brusch L; Hampe J; Zerial M
Nat Med; 2019 Dec; 25(12):1885-1893. PubMed ID: 31792455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
